311 related articles for article (PubMed ID: 27113237)
21. Evaluation of p16/Ki-67 dual-stain cytology performed on self-collected vaginal and clinician-collected cervical specimens for the detection of cervical pre-cancer.
Toliman PJ; Phillips S; de Jong S; O'Neill T; Tan G; Brotherton JML; Saville M; Kaldor JM; Vallely AJ; Tabrizi SN
Clin Microbiol Infect; 2020 Jun; 26(6):748-752. PubMed ID: 31654795
[TBL] [Abstract][Full Text] [Related]
22. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program.
Gök M; van Kemenade FJ; Heideman DA; Berkhof J; Rozendaal L; Spruyt JW; Beliën JA; Babovic M; Snijders PJ; Meijer CJ
Int J Cancer; 2012 Mar; 130(5):1128-35. PubMed ID: 21484793
[TBL] [Abstract][Full Text] [Related]
23. Colposcopy referral rate can be reduced by high-risk human papillomavirus triage in the management of recurrent atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology in Finland.
Jakobsson M; Tarkkanen J; Auvinen E; Häkkinen R; Laurila P; Tapper AM
Int J STD AIDS; 2012 Jul; 23(7):485-9. PubMed ID: 22844002
[TBL] [Abstract][Full Text] [Related]
24. Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions.
King J; Flores YN; Meneses-León J; Hernández-Salazar S; Robles-Rivera K; Rivera-Paredez B; León-Maldonado L; Hernández-López R; Torres-Ibarra L; Lazcano-Ponce E; Salmerón J
Cancer Prev Res (Phila); 2023 Dec; 16(12):681-687. PubMed ID: 37788346
[TBL] [Abstract][Full Text] [Related]
25. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
26. Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening.
Gustavsson I; Aarnio R; Myrnäs M; Hedlund-Lindberg J; Taku O; Meiring T; Wikström I; Enroth S; Williamson AL; Olovsson M; Gyllensten U
Virol J; 2019 Aug; 16(1):107. PubMed ID: 31438976
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.
Bais AG; van Kemenade FJ; Berkhof J; Verheijen RH; Snijders PJ; Voorhorst F; Babović M; van Ballegooijen M; Helmerhorst TJ; Meijer CJ
Int J Cancer; 2007 Apr; 120(7):1505-10. PubMed ID: 17205514
[TBL] [Abstract][Full Text] [Related]
29. Primary cervical screening with high risk human papillomavirus testing: observational study.
Rebolj M; Rimmer J; Denton K; Tidy J; Mathews C; Ellis K; Smith J; Evans C; Giles T; Frew V; Tyler X; Sargent A; Parker J; Holbrook M; Hunt K; Tidbury P; Levine T; Smith D; Patnick J; Stubbs R; Moss S; Kitchener H
BMJ; 2019 Feb; 364():l240. PubMed ID: 30728133
[TBL] [Abstract][Full Text] [Related]
30. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
[TBL] [Abstract][Full Text] [Related]
31. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.
Arbyn M; Smith SB; Temin S; Sultana F; Castle P;
BMJ; 2018 Dec; 363():k4823. PubMed ID: 30518635
[TBL] [Abstract][Full Text] [Related]
32. Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.
Stanczuk GA; Baxter GJ; Currie H; Forson W; Lawrence JR; Cuschieri K; Wilson A; Patterson L; Govan L; Black J; Palmer T; Arbyn M
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1629-1635. PubMed ID: 28887297
[No Abstract] [Full Text] [Related]
33. Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol.
Van Keer S; Peeters E; Vanden Broeck D; De Sutter P; Donders G; Doyen J; Tjalma WAA; Weyers S; Vorsters A; Arbyn M
Gynecol Oncol; 2021 Sep; 162(3):575-583. PubMed ID: 34172287
[TBL] [Abstract][Full Text] [Related]
34. Comparison of vaginal self-sampling and cervical sampling by medical professionals for the detection of HPV and CIN2+: A randomized study.
Aarnio R; Isacson I; Sanner K; Gustavsson I; Gyllensten U; Olovsson M
Int J Cancer; 2021 Jun; 148(12):3051-3059. PubMed ID: 33497465
[TBL] [Abstract][Full Text] [Related]
35. A comparison of high-risk human papillomavirus DNA detection between urine and cervical sample testing in women with abnormal Pap smears.
Punyashthira A; Horthongkham N; Jaishuen A; Jareemit N; Achariyapota V
J Obstet Gynaecol Res; 2022 Feb; 48(2):448-455. PubMed ID: 34750932
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
Song F; Du H; Wang C; Huang X; Wu R;
PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
[TBL] [Abstract][Full Text] [Related]
37. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
38. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
39. CyclinA1 Promoter Methylation in Self-Sampling Test.
Oranratanaphan S; Kengsakul M; Triratanachat S; Kitkumthorn N; Mutirangura A; Termrungruanglert W
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2913-2917. PubMed ID: 33112548
[TBL] [Abstract][Full Text] [Related]
40. Vaginal and Urine Self-sampling Compared to Cervical Sampling for HPV-testing with the Cobas 4800 HPV Test.
Asciutto KC; Henningsson AJ; Borgfeldt H; Darlin L; Borgfeldt C
Anticancer Res; 2017 Aug; 37(8):4183-4187. PubMed ID: 28739704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
